Abstract
Tyrosine hydroxylase (TH) is the rate-limiting enzyme in brain catecholamine biosynthesis, and tetrahydrobiopterin is its cofactor. Research has focused on identifying mechanisms of TH activity regulation. TH activity is modulated by the cofactor itself, and is enhanced by several kinases phosphorylating key serines in the TH regulatory domain. Aside from these, the mechanisms that control TH gene transcription and TH mRNA translation are also related with the regulation of TH activity. Parkinson’s disease (PD) is characterized by severe loss of dopaminergic neurons and depletion of dopamine in substantia nigra. Reduction of TH expression results in diminished dopamine synthesis and leads to PD; thus TH is essential in the pathogenesy of PD. It has also been shown that dysregulation of TH activity will contribute to PD. For example, α-synuclein represses TH not only by inhibiting phosphorylation at Ser40 of TH, but also by stimulating protein phosphatase 2A activity, which decreases dopamine synthesis and leads to parkinsonism. Based on these studies of TH in PD pathogenesis, a therapeutic strategy aimed to improve striatal TH expression in PD has received wide interest. Evidence shows that using drugs or other treatment methods such as gene replacement therapy to increase nigrostriatal TH expression is an effective therapy for PD. Further investigation of TH regulatory mechanisms will not only provide additional drug targets for PD, but may also help to identify new PD therapeutics.
Keywords: Parkinson’s disease, tyrosine hydroxylase, dopamine, tetrahydrobiopterin, phosphorylation, gene transcription.
CNS & Neurological Disorders - Drug Targets
Title:Overview of Tyrosine Hydroxylase in Parkinson’s Disease
Volume: 11 Issue: 4
Author(s): Yanzhen Zhu, Jing Zhang and Yanjun Zeng
Affiliation:
Keywords: Parkinson’s disease, tyrosine hydroxylase, dopamine, tetrahydrobiopterin, phosphorylation, gene transcription.
Abstract: Tyrosine hydroxylase (TH) is the rate-limiting enzyme in brain catecholamine biosynthesis, and tetrahydrobiopterin is its cofactor. Research has focused on identifying mechanisms of TH activity regulation. TH activity is modulated by the cofactor itself, and is enhanced by several kinases phosphorylating key serines in the TH regulatory domain. Aside from these, the mechanisms that control TH gene transcription and TH mRNA translation are also related with the regulation of TH activity. Parkinson’s disease (PD) is characterized by severe loss of dopaminergic neurons and depletion of dopamine in substantia nigra. Reduction of TH expression results in diminished dopamine synthesis and leads to PD; thus TH is essential in the pathogenesy of PD. It has also been shown that dysregulation of TH activity will contribute to PD. For example, α-synuclein represses TH not only by inhibiting phosphorylation at Ser40 of TH, but also by stimulating protein phosphatase 2A activity, which decreases dopamine synthesis and leads to parkinsonism. Based on these studies of TH in PD pathogenesis, a therapeutic strategy aimed to improve striatal TH expression in PD has received wide interest. Evidence shows that using drugs or other treatment methods such as gene replacement therapy to increase nigrostriatal TH expression is an effective therapy for PD. Further investigation of TH regulatory mechanisms will not only provide additional drug targets for PD, but may also help to identify new PD therapeutics.
Export Options
About this article
Cite this article as:
Zhu Yanzhen, Zhang Jing and Zeng Yanjun, Overview of Tyrosine Hydroxylase in Parkinson’s Disease, CNS & Neurological Disorders - Drug Targets 2012; 11 (4) . https://dx.doi.org/10.2174/187152712800792901
DOI https://dx.doi.org/10.2174/187152712800792901 |
Print ISSN 1871-5273 |
Publisher Name Bentham Science Publisher |
Online ISSN 1996-3181 |
Call for Papers in Thematic Issues
Diagnosis and treatment of central nervous system infectious diseases
Infectious diseases of the central nervous system (CNS) can be divided into bacterial, tuberculous, viral, fungal, parasitic infections, etc. Early etiological treatment is often the most crucial means to reduce the mortality rate of patients with central nervous system infections, reduce complications and sequelae, and improve prognosis. The initial clinical ...read more
Techniques of Drug Repurposing: Delivering a new life to Herbs & Drugs
Of late, with the adaptation of innovative approaches and integration of advancements made towards medical sciences as well as the availability of a wide range of tools; several therapeutic challenges are being translated into viable clinical solutions, with a high degree of efficacy, safety, and selectivity. With a better understanding ...read more
Trends and perspectives in the rational management of CNS disorders
Central nervous system (CNS) diseases enforce a significant global health burden, driving ongoing efforts to improve our understanding and effectiveness of therapy. This issue investigates current advances in the discipline, focusing on the understanding as well as therapeutic handling of various CNS diseases. The issue covers a variety of diseases, ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Non-Analgesic Effects of Opioids: Interactions Between Opioids and Other Drugs
Current Pharmaceutical Design The Surgical Management of Parkinson's Disease
CNS & Neurological Disorders - Drug Targets Neuroprotective Strategies for Parkinsons Disease
Current Neuropharmacology Phenytoin Induced Chorea: A Rare Adverse Effect of the Drug
Current Drug Safety Role of Kynurenines in the Central and Peripherial Nervous Systems
Current Neurovascular Research Antipsychotic Drug Effects in Schizophrenia: A Review of Longitudinal fMRI Investigations and Neural Interpretations
Current Medicinal Chemistry Prevalence, Severity and Characteristics of Tardive Dyskinesia Among Schizophrenia Patients in an Israeli Psychiatric Center
Current Psychopharmacology TRPV1 Channel: A Potential Drug Target for Treating Epilepsy
Current Neuropharmacology Optimization of Lentiviral Vectors Generation for Biomedical and Clinical Research Purposes: Contemporary Trends in Technology Development and Applications
Current Gene Therapy Pharmacological Treatments for Attention-Deficit/Hyperactivity Disorder (ADHD) in Adults
Current Psychiatry Reviews Editorial [Hot Topic: New Ligands at 5-HT and DA Receptors for the Treatment of Neuropsychiatric Disorders (Guest Editor: Giuseppe Di Giovanni) ]
Current Topics in Medicinal Chemistry 5-HT<sub>6</sub> Receptor Antagonists: Potential Efficacy for the Treatment of Cognitive Impairment in Schizophrenia
Current Pharmaceutical Design Therapeutic Potential of Cannabinoids in Neurodegenerative Disorders: A Selective Review
Current Pharmaceutical Design On the Pathogenesis and Neuroprotective Treatment of Parkinson Disease: What have we Learned from the Genetic Forms of this Disease?
Current Medicinal Chemistry Blocking Striatal Adenosine A2A Receptors: A New Strategy for Basal Ganglia Disorders
Recent Patents on CNS Drug Discovery (Discontinued) Moving Beyond Tyrosine Hydroxylase to Define Dopaminergic Neurons for Use in Cell Replacement Therapies for Parkinson’s Disease
CNS & Neurological Disorders - Drug Targets Advances in Discovery of PDE10A Inhibitors for CNS-Related Disorders. Part 1: Overview of the Chemical and Biological Research
Current Drug Targets Development of Tablet Device App for Parkinson’s Disease Patients’ Continuous Self-Monitoring and Management
Neuroscience and Biomedical Engineering (Discontinued) Combined Fine-Motor Tests and Self-Assessments for Remote Detection of Motor Fluctuations
Recent Patents on Biomedical Engineering (Discontinued) A Role of GABA Analogues in the Treatment of Neurological Diseases
Current Medicinal Chemistry